Why is the Volpara share price rocketing 13% today?

This health technology share is catching the eye with a very strong gain on Tuesday.

| More on:
A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price is taking off on Tuesday.

In afternoon trade, the health technology company's shares are up 13% to 72.5 cents.

Why is the Volpara share price rocketing?

Investors have been buying the company's shares today after responding very positively to its quarterly update.

According to the release, for the three months ended 30 September, Volpara reported record cash receipts of NZ$11.5 million. This was up 32% over the prior corresponding period.

In addition, the company finished the period with contracted annual recurring revenue (CARR) of ~US$28.4 million (~NZ$46.3 million), which is up over US$1.2 million since the end of June.

Also growing was Volpara's annual recurring revenue (ARR), which is now ~US$22.5 million (~NZ$36.6 million). This is up from US$21.5 million in the prior quarter.

But arguably the most important number on this release, and the one giving the Volpara share price the biggest lift, was its cash flow.

The company reported positive net operating cash flow of NZ$1.2 million for the quarter. This is the fourth consecutive quarter of positive net operating cash flow. Impressively, this means Volpara achieved its cash flow target 18 months ahead of plan.

In light of this achievement, the company is no longer required to provide Appendix 4C quarterly reporting updates. However, management advised that it remains committed to providing regular operational and financial updates to shareholders and will therefore release business updates periodically.

A milestone quarter

Volpara CEO's and Managing Director, Teri Thomas, appeared to be rightfully pleased with the quarter. Thomas said:

What a milestone quarter for us! I'm delighted to see current customers, happy with our software, expand their use of Volpara to save even more families from cancer. We had a record number of contracts up for renewal and customers have chosen to expand and extended their contracts with us for longer, with more software than ever before. Our record cash receipts reflect the positive impact we have on families, as happy customers pay their bills.

Our growth and financial strength, approaching US$100M TCV, allows us to turn increasingly to growth endeavours like a brand-new product, called Quiver, due out next year. Leveraging our Analytics platform, this new product provides administrative simplification for mammography centres so they can spend more time with patients. We do good and we do it well and that is reflected in this positive quarter.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Volpara Health Technologies. The Motley Fool Australia has positions in and has recommended Volpara Health Technologies. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »